Variable bleeding rates have been observed with different CAR constructs, with 30% of patients experiencing clinically significant bleeding after an investigational CD22-targeting CAR that was associated with lower-grade CRS but a greater degree of hypofibrinogenemia (< 150 mg/dL) [77] vs. 45.6% after tisa-cel which was associated with higher-grade CRS on the ELIANA and ENSIGN trials [78]. This evidence concerns the gene CD22 and congenital rubella syndrome.